What's Happening?
Symeres, a Netherlands-based CRDMO, has expanded its spray drying capabilities at its Cranbury, New Jersey site. This enhancement aims to support the formulation development of poorly soluble small-molecule drug candidates. The expansion includes advanced
bioavailability enhancement strategies such as amorphous solid dispersions and particle engineering. This development is part of Symeres' integrated CMC offering, which combines various scientific disciplines to streamline drug development processes from preclinical stages to Phase II clinical activities.
Why It's Important?
The expansion of Symeres' capabilities in New Jersey is significant for the pharmaceutical industry, particularly in the U.S., as it addresses the growing need for advanced formulation techniques to improve drug bioavailability. This development can accelerate the drug development process, reduce risks associated with tech transfers, and enhance the overall efficiency of bringing new drugs to market. For pharmaceutical companies, this means potentially faster and more cost-effective pathways to clinical trials and eventual market entry, which can lead to improved patient outcomes and competitive advantages in the industry.
